Fulvestrant has been approved by the U.S. Food and Drug Administration (FDA) for more than 10 years for the treatment of metastatic ER+ BC in postmenopausal women after tumor progression and after receiving anti-estrogen therapeutics such as tamoxifen. The gene discussed is ESR1; the disease is breast cancer.